Health Status and Preventive Health Services Among Reproductive-Aged Women in Treatment for Opioid Use Disorder

Overview

Journal Womens Health Rep (New Rochelle)

Date 2023 Jan 13

PMID 36636314

Authors

Vanessa L Short

Dennis J Hand

Lauren Pyfer

Hanna Steiger

Meghan Gannon

Gregory Jaffe

Diane J Abatemarco

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the utilization of preventive health services and the prevalence of chronic health conditions among a cohort of women in treatment for opioid use disorder (OUD).

Methods: Ninety-seven women who were receiving treatment for OUD from a single urban treatment program completed a self-administered anonymous online questionnaire that asked about demographics, health, receipt of preventive health services, and utilization of health care. Descriptive statistics were used to describe data.

Results: More than one-third of respondents reported that their health was fair or poor, whereas one-quarter were very concerned with their health. Most participants (59%) reported at least one chronic health condition; nearly 1 in 5 reported two or more conditions. Less than half of respondents had received a routine medical examination in the past year. Vaccine uptake was low; 56% received the coronavirus disease 2019 vaccine and 36% received the annual influenza vaccine.

Conclusions: Women in treatment for OUD could benefit from enhanced health care to address the high rates of chronic diseases and risk factors and underutilization of recommended preventive health services. Interventions and models of care that aim to enhance utilization of such services, and ultimately improve the health of this vulnerable population, may be worth exploring.

References

Leslie D, Ba D, Agbese E, Xing X, Liu G . The economic burden of the opioid epidemic on states: the case of Medicaid. Am J Manag Care. 2019; 25(13 Suppl):S243-S249. View

Haight S, Ko J, Tong V, Bohm M, Callaghan W . Opioid Use Disorder Documented at Delivery Hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2018; 67(31):845-849. PMC: 6089335. DOI: 10.15585/mmwr.mm6731a1. View

Terplan M, Hand D, Hutchinson M, Salisbury-Afshar E, Heil S . Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review. Prev Med. 2015; 80:23-31. PMC: 4842019. DOI: 10.1016/j.ypmed.2015.04.008. View

Haddad M, Zelenev A, Altice F . Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015; 92(1):193-213. PMC: 4338126. DOI: 10.1007/s11524-014-9924-1. View

Short V, Gannon M, Weingarten W, Kaltenbach K, LaNoue M, Abatemarco D . Reducing Stress Among Mothers in Drug Treatment: A Description of a Mindfulness Based Parenting Intervention. Matern Child Health J. 2017; 21(6):1377-1386. DOI: 10.1007/s10995-016-2244-1. View

Holbrook A, Kaltenbach K . Co-occurring psychiatric symptoms in opioid-dependent women: the prevalence of antenatal and postnatal depression. Am J Drug Alcohol Abuse. 2012; 38(6):575-9. DOI: 10.3109/00952990.2012.696168. View

Holbrook A, Baxter J, Jones H, Heil S, Coyle M, Martin P . Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction. 2012; 107 Suppl 1:83-90. PMC: 4368056. DOI: 10.1111/j.1360-0443.2012.04042.x. View

Benjamin-Johnson R, Moore A, Gilmore J, Watkins K . Access to medical care, use of preventive services, and chronic conditions among adults in substance abuse treatment. Psychiatr Serv. 2009; 60(12):1676-9. DOI: 10.1176/ps.2009.60.12.1676. View

Almario C, Seligman N, Dysart K, Berghella V, Baxter J . Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009; 201(3):326.e1-6. DOI: 10.1016/j.ajog.2009.05.052. View

10.

Florence C, Luo F, Rice K . The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2020; 218:108350. PMC: 8091480. DOI: 10.1016/j.drugalcdep.2020.108350. View

11.

Vallecillo G, Robles M, Torrens M, Samos P, Roquer A, Martires P . Metabolic syndrome among individuals with heroin use disorders on methadone therapy: Prevalence, characteristics, and related factors. Subst Abus. 2017; 39(1):46-51. DOI: 10.1080/08897077.2017.1363122. View

12.

Wang Q, Kaelber D, Xu R, Volkow N . COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020; 26(1):30-39. PMC: 7488216. DOI: 10.1038/s41380-020-00880-7. View

13.

Melbostad H, Badger G, Rey C, MacAfee L, Dougherty A, Sigmon S . Contraceptive Knowledge among Females and Males Receiving Medication Treatment for Opioid Use Disorder Compared to Those Seeking Primary Care. Subst Use Misuse. 2020; 55(14):2403-2408. PMC: 7712494. DOI: 10.1080/10826084.2020.1823418. View

14.

Goodman D . Improving Access to Maternity Care for Women with Opioid Use Disorders: Colocation of Midwifery Services at an Addiction Treatment Program. J Midwifery Womens Health. 2016; 60(6):706-12. DOI: 10.1111/jmwh.12340. View

15.

Hand D, Short V, Abatemarco D . Treatments for opioid use disorder among pregnant and reproductive-aged women. Fertil Steril. 2017; 108(2):222-227. DOI: 10.1016/j.fertnstert.2017.06.011. View

16.

Smith V, Wilson C . Families Affected by Parental Substance Use. Pediatrics. 2016; 138(2). DOI: 10.1542/peds.2016-1575. View

17.

Akerman S, Brunette M, Green A, Goodman D, Blunt H, Heil S . Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. J Subst Abuse Treat. 2015; 52:40-7. PMC: 4382443. DOI: 10.1016/j.jsat.2014.12.002. View

18.

Fiellin D, OConnor P, Chawarski M, Pakes J, Pantalon M, Schottenfeld R . Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001; 286(14):1724-31. DOI: 10.1001/jama.286.14.1724. View

19.

Walker E, Druss B . Cumulative burden of comorbid mental disorders, substance use disorders, chronic medical conditions, and poverty on health among adults in the U.S.A. Psychol Health Med. 2016; 22(6):727-735. PMC: 5564203. DOI: 10.1080/13548506.2016.1227855. View

20.

Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T . Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; 370:m3320. PMC: 7459193. DOI: 10.1136/bmj.m3320. View